司美格鲁肽去年卖了2508亿元

Core Insights - Novo Nordisk's flagship product, semaglutide, achieved global sales of 228.29 billion Danish Krone (approximately 250.84 billion yuan) in the last year, marking a year-on-year growth of over 10% [2] - The sales breakdown includes Ozempic (1,270.89 billion DKK), Wegovy (791.06 billion DKK), and oral semaglutide (220.93 billion DKK) [2] - In the Chinese market, semaglutide products generated a total sales of 68.15 billion DKK (approximately 7.49 billion yuan) [2] - Novo Nordisk's overall revenue reached 309.06 billion DKK, a 6% increase year-on-year, with a net profit of 102.43 billion DKK, up 1% [2] Challenges and Market Dynamics - 2023 poses significant challenges for Novo Nordisk as the core compound patent for semaglutide will expire in some international markets, including China on March 20 [3] - The expiration of the patent is expected to lead to price competition from generic drugs, with 10 semaglutide generics already filed for market approval in China and 11 more in Phase III clinical trials [3] - The company has lowered its overall performance expectations for 2023, forecasting a revenue decline of 5% to 13% for 2026, significantly exceeding market expectations due to U.S. drug price reduction policies and patent expirations [3] Strategic Responses - In response to the patent expiration, Novo Nordisk is launching an oral GLP-1 weight loss drug, Wegovy, which was approved in the U.S. in December and has seen a weekly prescription volume of approximately 50,000 since its launch [4] - The company is also working on stronger weight loss GLP-1 drugs, having submitted new drug applications for a 7.2 mg semaglutide injection and CagriSema, a combination of cagrilintide and semaglutide [4] - Clinical trials for CagriSema have shown significant weight loss results, with a 22.7% reduction in weight over 68 weeks for patients continuing treatment [4] - Novo Nordisk anticipates continued growth in the global GLP-1 market and aims to expand patient coverage and sales through new therapies [4]